These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 30503852)

  • 21. Integrating Biomarkers and Targeted Therapy Into Colorectal Cancer Management.
    Lieu CH; Corcoran RB; Overman MJ
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():207-215. PubMed ID: 31099678
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value.
    Jiang X; Pissaloux D; De La Fouchardiere C; Desseigne F; Wang Q; Attignon V; Fondrevelle ME; De La Fouchardiere A; Perol M; Cassier P; Seigne C; Perol D; Ray-Coquard I; Meeus P; Fayette J; Flechon A; Le Cesne A; Penel N; Tredan O; Blay JY
    Oncotarget; 2015 Sep; 6(28):26388-99. PubMed ID: 26317543
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selected Articles from This Issue.
    Clin Cancer Res; 2020 May; 26(10):2279. PubMed ID: 32414759
    [No Abstract]   [Full Text] [Related]  

  • 24. Molecular pathway activation - New type of biomarkers for tumor morphology and personalized selection of target drugs.
    Buzdin A; Sorokin M; Garazha A; Sekacheva M; Kim E; Zhukov N; Wang Y; Li X; Kar S; Hartmann C; Samii A; Giese A; Borisov N
    Semin Cancer Biol; 2018 Dec; 53():110-124. PubMed ID: 29935311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular therapy as a future strategy in endometrial cancer.
    Thanapprapasr D; Thanapprapasr K
    Asian Pac J Cancer Prev; 2013; 14(6):3419-23. PubMed ID: 23886121
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted Cancer Therapies World Congress 2010--part 2. 21-23 September 2010, Zurich, Switzerland.
    Youssoufian H
    IDrugs; 2010 Dec; 13(12):833-5. PubMed ID: 21154137
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted therapy in cancer.
    Tsimberidou AM
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1113-32. PubMed ID: 26391154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Editorial for the Special Issue "New Strategies in Cancer Pharmacotherapy: Development of Hormonal Antineoplastic Drugs, Cytotoxic Drugs and Targeted Therapies".
    Martínez-Campa C; Alonso-González C
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32521599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biomarker-Driven and Molecular Targeted Therapies for Hepatobiliary Cancers.
    Harris WP; Wong KM; Saha S; Dika IE; Abou-Alfa GK
    Semin Oncol; 2018 Jun; 45(3):116-123. PubMed ID: 30348531
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical aspects for survivin: a crucial molecule for targeting drug-resistant cancers.
    Singh N; Krishnakumar S; Kanwar RK; Cheung CH; Kanwar JR
    Drug Discov Today; 2015 May; 20(5):578-87. PubMed ID: 25433305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biomarkers to assess the targeting of DNA repair pathways to augment tumor response to therapy.
    Nowsheen S; Whitley AC; Yang ES
    Curr Mol Med; 2012 Jul; 12(6):788-803. PubMed ID: 22292444
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nampt/Visfatin/PBEF: a functionally multi-faceted protein with a pivotal role in malignant tumors.
    Jieyu H; Chao T; Mengjun L; Shalong W; Xiaomei G; Jianfeng L; Zhihong L
    Curr Pharm Des; 2012; 18(37):6123-32. PubMed ID: 22934941
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted anti-cancer therapy in the elderly.
    Gonsalves W; Ganti AK
    Crit Rev Oncol Hematol; 2011 Jun; 78(3):227-42. PubMed ID: 20599391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transglutaminase-2: evolution from pedestrian protein to a promising therapeutic target.
    Agnihotri N; Mehta K
    Amino Acids; 2017 Mar; 49(3):425-439. PubMed ID: 27562794
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic antibodies against cancer stem cells: a promising approach.
    Sneha S; Nagare RP; Priya SK; Sidhanth C; Pors K; Ganesan TS
    Cancer Immunol Immunother; 2017 Nov; 66(11):1383-1398. PubMed ID: 28840297
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lessons learned from a SIRT2-selective inhibitor.
    Jing H; Lin H
    Oncotarget; 2016 Apr; 7(17):22971-2. PubMed ID: 27050282
    [No Abstract]   [Full Text] [Related]  

  • 37. The future of combination treatment with checkpoint inhibitors in melanoma.
    Sullivan RJ
    Clin Adv Hematol Oncol; 2019 Feb; 17(2):96-99. PubMed ID: 30845111
    [No Abstract]   [Full Text] [Related]  

  • 38. Progress and potential impact of RET kinase targeting in cancer.
    Mulligan LM
    Expert Rev Proteomics; 2016 Jul; 13(7):631-3. PubMed ID: 27337654
    [No Abstract]   [Full Text] [Related]  

  • 39. Receptor Tyrosine Kinase-Targeted Cancer Therapy.
    Yamaoka T; Kusumoto S; Ando K; Ohba M; Ohmori T
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404198
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targetable long non-coding RNAs in cancer treatments.
    Chen L; Dzakah EE; Shan G
    Cancer Lett; 2018 Apr; 418():119-124. PubMed ID: 29341880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.